Previous 10 | Next 10 |
Significant reduction of levodopa-induced dyskinesia by AV-101 observed in "gold standard" MPTP non-human primate model of Parkinson's disease, while maintaining antiparkinsonian activity of levodopa and without causing amantadine-like adverse effects SOUTH SAN FRANCISCO, CA / ACCESSWIRE...
New preclinical data involving pregabalin are consistent with peer-reviewed data involving gabapentin previously published in The Journal of Pain SOUTH SAN FRANCISCO, CA / ACCESSWIRE / May 30, 2019 / VistaGen Therapeutics (NASDAQ: VTGN), a clinical-stage biopharmaceutical company ...
SOUTH SAN FRANCISCO, CA / ACCESSWIRE / May 7, 2019 / VistaGen Therapeutics (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for depression, social anxiety disorder and other central nervous system (CNS) diseases and disorders with high unmet ne...
Gainers: Diffusion Pharmaceuticals (NASDAQ: DFFN ) +49% . ARCA biopharma (NASDAQ: ABIO ) +47% . Digimarc Corporation (NASDAQ: DMRC ) +46% . Hudson Technologies (NASDAQ: HDSN ) +23% . InspireMD (NYSEMKT: NSPR ) +17% . Materion Corporation (NYSE: MTRN ) +16% . Precipio (NASD...
Thinly traded nano cap VistaGen Therapeutics ( OTC:VTGN -44.8% ) slumps on almost a 5x surge in volume in reaction to the unsuccessful outcome of an exploratory Phase 2 clinical trial assessing lead candidate AV-101 as monotherapy in patients with treatment-resistant depression. M...
Eventbrite (NYSE: EB ) -34% on Q1 earnings . More news on: Eventbrite, Inc., VistaGen Therapeutics, Inc., ABIOMED, Inc., Stocks on the move, Read more ...
SOUTH SAN FRANCISCO, CA / ACCESSWIRE / May 2, 2019 / VistaGen Therapeutics (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for depression, social anxiety disorder and other central nervous system (CNS) diseases and disorders with high unmet n...
SOUTH SAN FRANCISCO, CA / ACCESSWIRE / April 3, 2019 / VistaGen Therapeutics (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for depression and other central nervous system (CNS) diseases and disorders with high unmet need, today announced tha...
PH94B has potential to be the First FDA-Approved PRN Treatment for Social Anxiety Disorder New Findings Presented at the 2019 Anxiety and Depression Association of America Annual Conference SOUTH SAN FRANCISCO, CA / ACCESSWIRE / April 1, 2019 / VistaGen Therapeutics (NASDAQ: VTGN...
SOUTH SAN FRANCISCO, CA / ACCESSWIRE / March 28, 2019 / VistaGen Therapeutics (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for depression, social anxiety disorder and other central nervous system (CNS) diseases and disorders with high unm...
News, Short Squeeze, Breakout and More Instantly...
VistaGen Therapeutics Inc. Company Name:
VTGN Stock Symbol:
NASDAQ Market:
VistaGen Therapeutics Inc. Website:
Vistagen Therapeutics (NASDAQ: VTGN ), a clinical-stage, neuroscience-focused biopharmaceutical company dedicated to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on nose-to-brain neurocircuitry, has received multiple new patent...
Vistagen (Nasdaq: VTGN), a clinical-stage neuroscience-focused biopharmaceutical company dedicated to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on nose-to-brain neurocircuitry, today announced the broadening of its global in...
Vistagen (NASDAQ: VTGN) , a biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological disorders, today announced that it has been recognized by Mental Health America (“MHA”) for its dedication to pr...